Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Urology"
DOI: 10.1097/ju.0000000000001633
Abstract: PURPOSE Recurrent disease after BCG presents a therapeutic challenge. To aid trial development, the US Food & Drug Administration defined 'adequate BCG' therapy and adopted the 'BCG unresponsive' disease state. Available data for efficacy benchmark… read more here.
Keywords: muscle; bcg therapy; cancer; adequate bcg ... See more keywords
Contemporary outcomes of bladder carcinoma in situ treated with an adequate BCG immunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "BJU international"
DOI: 10.1111/bju.15567
Abstract: OBJECTIVE To assess whether bacillus Calmette-Guérin (BCG) responsiveness after initiation of an adequate BCG treatment (at least five of six instillations of induction and at least two of three instillations of maintenance) impacts oncological outcomes… read more here.
Keywords: bcg immunotherapy; adequate bcg; bcg unresponsive; months iqr ... See more keywords